SG Americas Securities’s Structure Therapeutics GPCR Stock Holding History

SG Americas Securities’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$128K	Sell	2,649 -7,498	-74%	-$513K	﹤0.01%	2834
2025 Q4	$706K	Sell	10,147 -29,553	-74%	-$1.21M	﹤0.01%	2289
2025 Q3	$1.11M	Buy	39,700 +20,461	+106%	+$408K	﹤0.01%	1362
2025 Q2	$399K	Buy	+19,239	New	+$423K	﹤0.01%	1813
2025 Q1	–	Sell	-5,445	Closed	-$148K	–	3578
2024 Q4	$148K	Sell	5,445 -2,911	-35%	-$103K	﹤0.01%	2415
2024 Q3	$367K	Buy	+8,356	New	+$323K	﹤0.01%	1961

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

SG Americas Securities's GPCR Position: Q1 2026 in Review

SG Americas Securities reduced its Structure Therapeutics (GPCR) stake by 74% in Q1 2026, selling an estimated $513K and leaving 2,649 shares worth $128K. The position accounts for ﹤0.01% of the portfolio, ranked #2834.

SG Americas Securities first reported a position in GPCR in Q3 2024 and has held it in 6 quarters since. The position peaked at $1.11M in Q3 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

SG Americas Securities held 2,649 shares of Structure Therapeutics worth $128K as of Q1 2026.
SG Americas Securities sold 7,498 Structure Therapeutics shares in Q1 2026, an estimated $513K.
Structure Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q1 2026, its #2834 holding.
SG Americas Securities first reported a position in Structure Therapeutics in Q3 2024 and has held it in 6 quarters since.
SG Americas Securities's Structure Therapeutics position peaked at $1.11M in Q3 2025.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.